Economic and comorbidity burden among patients with moderate-to-severe psoriasis

Journal of Managed Care Pharmacy

Volumn 21, Issue 10, 2015, Pages 874-888

  Feldman, Steven R ^a   Zhao, Yang ^b   Shi, Lizheng ^d   Tran, Mary Helen ^c  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c SANOFI   (France)

^d TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE COURSE; DRUG USE; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; OUTPATIENT CARE; PHOTOTHERAPY; PRESCRIPTION; PREVALENCE; PSORIASIS; PSORIATIC ARTHRITIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK; STATISTICAL ANALYSIS; SYSTEMIC THERAPY; YOUNG ADULT; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE HEART INFARCTION; ANXIETY; AUTOIMMUNE DISEASE; CEREBROVASCULAR DISEASE; CROHN DISEASE; DATA BASE; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; HEMIPLEGIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; LYMPHOMA; MULTIPLE SCLEROSIS; OBESITY; OUTPATIENT; PEPTIC ULCER; PERIPHERAL VASCULAR DISEASE; RHEUMATOID ARTHRITIS; SKIN CANCER; ULCERATIVE COLITIS; ADOLESCENT; CASE CONTROL STUDY; COST OF ILLNESS; ECONOMICS; EMERGENCY HEALTH SERVICE; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT;

ADOLESCENT; ADULT; BIOLOGICAL PRODUCTS; CASE-CONTROL STUDIES; COMORBIDITY; COST OF ILLNESS; DERMATOLOGIC AGENTS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PHOTOTHERAPY; PSORIASIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84946231844     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.10.874     Document Type: Article

References (38)

1. National Psoriasis Foundation. Statistics. Available at: https://www.psoriasis. org/cure_known_statistics. Accessed September 6, 2015.
2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-39.
3. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the U.S. population. J Am Acad Dermatol. 2004;51(5):704-08.
4. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 41(3 Pt 1):401-07.
5. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-41.
6. Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol. 2010;24(8):885-92.
7. Vena GA, Vestita M, Cassano N. Can early treatment with biologicals modify the natural history of comorbidities? Dermatol Ther. 2010;23(2):181-93.
8. Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. Am J Med. 2009;122(12):1150.
9. Kimball AB, Guerin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25(2):157-63.
10. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003;4(7):441-47.
11. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol. 2006;24(5):438-47.
12. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14-ii17.
13. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;3(2):26.
14. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011;147(4):419-24.
15. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-35.
16. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10):2411-18.
17. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173-79.
18. Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006;55(3):490-500.
19. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. J Dermatolog Treat. 2012;23(4):240-54.
20. Feldman SR, Evans C, Russell MW. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatolog Treat. 2005;16(1):37-42.
21. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59(5):772-80.
22. Yu AP, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin. 2009;25(10):2429-38.
23. Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012;51(12):1432-40.
24. Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013;14(4):315-26.
25. Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011;22(2):65-74.
26. Fonia A, Jackson K, Lereun C, Grant DM, Barker JN, Smith CH. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol. 2010;163(4):807-16.
27. Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the U.S. Curr Med Res Opin. 2004;20(12):1929-36.
28. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46(6):850-60.
29. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075-79.
30. U.S. Bureau of Labor Statistics. Consumer Price Index databases. Available at: http://www.bls.gov/cpi/data.htm. Accessed September 6, 2015.
31. Mullahy J. Specification and testing of some modified count data models. J Econometrics. 1986;33(3):341-65.
32. Poi BP. From the help desk: Some bootstrapping techniques. Stata J. 2004;4(3):312-28.
33. Kimball AB, Robinson JD, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two U.S. healthcare databases, 2001-2002. Dermatology. 2008;217(1):27-37.
34. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.
35. Wu JJ, Nguyen TU, Poon K-YT, Herrinton LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012;67(5):924-30.
36. Stern RS, Scotto J, Fears TR. Psoriasis and susceptibility to nonmelanoma skin cancer. J Am Acad Dermatol. 1985;12(1 Pt 1):67-73.
37. Gelfand JM, Shin DB, Neimann AL, Xingmei W, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126(10):2194-201.
38. Velez NF, Wei-Passanese EX, Husni ME, Mody EA, Qureshi AA. Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. Arch Dermatol Res. 2012;304(1):7-13.